Riamilovir

Source: Wikipedia, the free encyclopedia.
(Redirected from
Triazavirin
)
Riamilovir
Clinical data
Other namesTZV, Triazavirin
ATC code
  • None
Identifiers
  • 2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-c] [1,2,4]triazin-7(4H)-one
JSmol)
  • CSc1[nH]n2c(=O)c(nnc2n1)[N+](=O)[O-]
  • InChI=1S/C5H4N6O3S/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5/h1H3,(H,6,8,9)
  • Key:IDVQGNMSSHPZSJ-UHFFFAOYSA-N

Riamilovir is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical.[1] It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[2]

The main principle action of triazavirin is to inhibit the synthesis of viral ribonucleic acid (RNA) and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides.[3][4][5]

Uses

It was originally developed as a potential treatment for pandemic

Ebola virus disease.[11][12][13][14][15] Triazavirin has passed clinical trials and has shown antiviral activity against ARVI.[16][17][18][19] In 2020, testing of triazavirin was started against SARS-CoV-2 in Russia, China, and South Africa. [20][21][22][23][24][25][excessive citations
] The mechanism of action of Triazavirin is still controversial. No experimental biochemical studies on the activity of Triazavirin relating to SARS-CoV-2 or influenza target proteins have so far been published.[26]

In August 2014, the Ministry of Health of Russia issued a registration certificate for triazavirin.[27] The active substance of the drug triazavirin is a new active molecule,[2] and can be dispensed by prescription. The production of triazavirin is carried out at a modern pharmaceutical enterprise LLC "Plant Medsintez".[1] The registration procedure for triazavirin has begun in the Republic of South Africa.[24]

Criticism

The studies of Triazavirin were non-blinded and non-randomized, and included 66 patients only with, with 44 in a control group.[16]

References

  1. ^ a b "Triazaverin Is Officially Recommended". www.medsintez.com. Retrieved 2021-02-25.
  2. ^
    S2CID 83702396
    .
  3. ^
    PMID 20194696
    .
  4. ^
    PMID 25051708
    .
  5. ^
    PMID 19275052
    .
  6. PMID 23477247
    .
  7. S2CID 241604614
    .
  8. doi:10.20953/1729-9225-2017-3-25-32
    .
  9. PMID 26863736
    .
  10. doi:10.18527/2500-2236-2017-4-1-52-57
    .
  11. ^ "Target: Ebola". Pravda. 2014-12-22. Retrieved 18 January 2015.
  12. ^ "Yekaterinburg pharmacies to sell domestic antiviral drug". Yekaterinburg News Reports. 6 January 2015. Archived from the original on 18 January 2015. Retrieved 18 January 2015.
  13. ^ Cox S (2014-10-17). "Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014". BBC News.
  14. ^ Bora K (12 November 2014). "Russia Will Begin Testing Triazavirin, Used For Lassa Fever, And Other Drugs On Ebola: Health Ministry". International Business Times.
  15. ^ Kezina D (12 November 2014). "New antiviral drug from Urals will help fight Ebola and other viruses". Russia Beyond the Headlines.
  16. ^
    ISSN 2587-9359
    .
  17. ^ Verevshchikov VK, Shemyakina EK, Sabitov AU, Khamanova YB (2019). "The Possibilities of Etiotropic Therapy for Influenza and ARVI with Taking into Account the Period of Hospitalization and the Risk of Developing Secondary Complications". Antibiotics and Chemotherapy. Retrieved 2021-02-25.
  18. PMID 33720589
    .
  19. ^ Verevshchikov VK, Shemyakina EK, Sabitov AU, Batskalevich NA (2018). "Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology". Antibiotics and Chemotherapy. Retrieved 2021-02-25.
  20. ^ Jamshaid U (4 February 2020). "China Testing Russia's Triazavirin As Coronavirus Treatment". Russian Health Ministry. Urdupoint.
  21. ^ Phiri C (5 February 2020). "China Tests Russian Antiviral Drug Which Might Treat Coronavirus As Moscow Warns Of Possible 'Mass Outbreak'". Zambia Reports. Archived from the original on 5 February 2020. Retrieved 11 February 2020.
  22. S2CID 221520816
    .
  23. ^ Brandt K. "SA study to trial antiviral Triazavirin as COVID-19 treatment". ewn.co.za. Retrieved 2021-02-25.
  24. ^ a b "Discussion on Russia's antiviral drug Triazavirin". SABC News. 21 January 2021 – via YouTube.
  25. S2CID 229508119
    .
  26. PMID 36498864
    .
  27. ^ "Triazavirin (Riamilovir)". State Register of Medicines of the Russian Federation (in Russian).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Riamilovir&oldid=1214492117"